Can a quick strike drug stop MS in its tracks?
NCT ID NCT05418010
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether giving the drug natalizumab (Tyruko) within two weeks of first MS symptoms can help repair nerve damage. Forty adults with a first episode of MS-like inflammation will receive either the drug or a placebo. The main goal is to see if early treatment improves nerve healing on brain scans after 12 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Natalizumab (Tyruko), a drug that calms the immune system to reduce inflammation in the brain and spinal cord.
What this could lead to
If it works, this could show that starting a strong MS drug very early after first symptoms helps repair nerve damage and leads to better long-term outcomes.
What could go wrong
This is a small, early-phase trial with only 40 people. The drug may not improve nerve repair, and it carries risks like serious brain infections (PML) with long-term use.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Royal London Hospital
NOT_YET_RECRUITINGLondon, E1 1FR, United Kingdom
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
St George's Hospital
RECRUITINGLondon, SW17 0QT, United Kingdom
Contact Email: •••••@•••••